Best Life Sciences Platforms and Tools Companies in Gyeonggi-do, South Korea
The 36 best Life Sciences Platforms and Tools companies in Gyeonggi-do, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CHA Biotech.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Gyeonggi-do
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CHA Biotech Developer of stem cell therapeutics 40Funding top 23%News top 31%Partners top 32%Moat top 38% All 11 signals ▾Fundingtop 23% Newstop 31% Partnerstop 32% Moattop 38% Growthtop 42% Patentstop 43% Talentbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 36% Globalbottom 35% Funding: Raised $67.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) News: 5 BI events in 12 mo (of 12 tracked, 5 types) · +25% YoY rank vs industry peers · Fliar Intelligence Index 40/100 | $68M | 8 mo ago | Public | Sang Oh CEO | 2000 | WordPressMySQLPHP+11 | 74 patents Patents concentrated in health & consumer products | — |
| 2 | Advanced Protein Technologies Developer of biomaterials based on recombinant protein production technology | $17M | 58 mo ago | Series B | Chul Shin CEO | 2001 | — | 65 patents Production and therapeutic use of 2'-fucosyllactose oligosaccharides in nutrition and medicine | — |
| 3 | Speclipse Provider of molecular spectroscopy systems for early-stage skin cancer detection | $11M | 61 mo ago | Acquired | — | 2015 | GnuboardMySQLPHP+11 | 124 patents Patents concentrated in health & consumer products | — |
| 4 | MBD Biotech Provider of drug efficacy and toxicity testing services | $10M | — | Series B | Bo Ku CEO | 2015 | — | — | — |
| 5 | Novelty Nobility Developer of therapeutics for eye and cancer diseases | $8M | 79 mo ago | Series A | Sang Park Founder & CEO | 2018 | — | 55 patents Patents concentrated in chemistry & materials | — |
| 6 | AbTis Provider of technology for antibody-drug conjugation | $4M | 99 mo ago | Seed | Sang Jeon Chung Founder & CEO | 2016 | — | 65 patents Site-specific antibody‑drug conjugates and Fc‑binding linker technologies for targeted therapeutics | — |
| 7 | OPTOLANE Semiconductor-based molecular diagnostic & immunoassay POC platforms | — | 63 mo ago | Series C | Do Young Lee CEO | 2012 | — | 18 patents Integrated microfluidic biochips for PCR, cell analysis, and enhanced fluorescence detection | — |
| 8 | Biobank Healing Developer of a research platform for the prevention and treatment of diseases using intestinal microbes | — | 87 mo ago | Seed | Dongho Lee CEO | 2016 | PHPGSAPNginx+9 | — | — |
Top 10 Life Sciences Platforms and Tools companies in Gyeonggi-do
#1
Public · Seongnam-si, Gyeonggi-do · founded 2000$67.8Mraised▾
Developer of stem cell therapeutics. The company's pluripotent stem cells therapeutics include hESC-RPE (embryonic-derived RPE cells) and SCNT-RPE (somatic cell replication RPE cells) used to treat Stargardt disease and atrophic age-related macular degeneration. The company's adult stem cells therapeutic includes PLX-PAD (placental mesenchymal-like cells) for Intermittent Lameness and Severe limb ischemia, eCASs (enhanced umbilical cord stem cells) for acute stroke and degenerative disc disease, fetal–NPC (Nerve Progenitor Cell) for Parkinson's disease, and adipose-derived mesenchymal stem cells for degenerative lumbar vertebra. The company also aims to develop immune cell therapy to treat Relapsed glioblastoma.
- Jan 2026Post IPO$67.8M
#2
Series B · Suwon-si, Gyeonggi-do · founded 2001 · 11 employees$17.3Mraised▾
Developer of biomaterials based on recombinant protein production technology. The platform is manufacturing and developing protein products that can be used for medicine, food, and the cosmetic industry. The platform has developed the proprietary technology rProtein Manufacturing AD-Pure System for the production of recombinant protein.
- Nov 2021Series B$17.3M
- 2018Seed—
#3
Acquired · Seongnam-si, Gyeonggi-do · founded 2015 · 12 employees$10.6Mraised▾
Provider of molecular spectroscopy systems for early-stage skin cancer detection. It has developed a non-invasive diagnostic tool based on laser spectroscopy and statistical algorithm for early-stage skin cancer detection. This in-vivo laser technology works by analyzing the chemical composition of the tissues.
- Aug 2021Series A$8M
- Nov 2016Seed$2.6M
#4
Series A · Seongnam-si, Gyeonggi-do · founded 2018 · 33 employees$8.4Mraised▾
Novelty nobility is developing the therapeutics for eye and cancer diseases. The company has ongoing clinical trials on NN3201, NN3901, and NN2901 for ophthalmology and eye disease indications. The company uses technology as the SCF/c-KIT pathway as a drug target.
- Feb 2020Series A$8.4M
#5
Series B · Suwon-si, Gyeonggi-do · founded 2015 · 30 employees$10.2Mraised▾
mbdbiotech has developed a chip structure of pillar/well called Cellvitro for the testing of efficacy and toxicity. The company has also developed the dispensor and scanning machines(ASFA™) for 3D cell culture based on hydrogel encapsulation to predict the interaction or the reactivity of drugs in human body through .
- Series B$10.2M
#6
Seed · Suwon-si, Gyeonggi-do · founded 2016 · 24 employees$4.5Mraised▾
Abtis provides the technology for antibody-drug conjugation. It offers its proprietary technology AbTis linker for site-specific binding and AbTis Michelle for drug solubility. Its pipeline product also includes mAbs drug conjugates.
- Jun 2018Seed$4.5M
#7
Series C · Seongnam-si, Gyeonggi-do · founded 2012 · 116 employees—raised▾
OPTOLANE Technologies is developing the semiconductor-based POC molecular diagnostics platforms. The company's flagship products are MDx reader systems such as OPTOLANE's PCR, microarray PCR & digital PCR platforms (based on molecular diagnostic processes). Also developing immunoassay based reader platforms & sample preparation devices. All these systems are based on CMOS (complementory metal oxides semiconductors) biosensors.
- 2021Series C—
#8
Seed · Seongnam-si, Gyeonggi-do · founded 2016—raised▾
Biobank Healing helps in the prevention and treatment of disease by using intestinal microbes. The company develops transplant solutions using bacterial flora to treat disease. It helps to treat digestive diseases (CDI infection, gastric cancer, colon cancer, colon polyps, irritable bowel syndrome), rare intractable diseases, inflammatory diseases (ulcerative colitis, Crohn's disease, and autoimmune diseases), endocrine metabolic diseases (diabetes, high calcium blood, high blood pressure, and obesity), and neurological diseases (Parkinson's disease, autism, depression, ADHD, and Alzheimer's disease).
- 2019Seed—
#9
Public · Seongnam-si, Gyeonggi-do · founded 2000 · 60 employees—raised▾
Gene Matrix develops nucleic acid based assays for infectious and genetic diseases. Its proprietary Restriction Fragment Mass Polymorphism (RFMP) technology uses the mass of fragmented gene sequences to identify polymorphisms and other mutations. It has diagnostic products for hepatitis B&C, HPV and congenital hearing loss. In addition, tests for HIV/AIDS and the flu are under development.
- Nov 2007Series A—
#10
Series C · Ansan-si, Gyeonggi-do · founded 2000—raised▾
Humanscan is focused on research and development of a variety of probes for imaging techniques. The company has developed a range of single crystal based ultrasound probes. The single crystal offers wider bandwidth and higher sensitivity resulting in precise diagnosis. The company offers a variety of probes in different shapes including "Linear array, Convex array, Phased array, Matrix array, and Multi-channel HIFU probe for cancer treatment. The company has 5 patents in ultrasound diagnostic imaging ’Probe’.
- 2007Series C—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in South Korea
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,344 South Korea-affiliated papers.
- Ministry of Education187
- Seoul National University134
- Yonsei University85
- Ministry of Agriculture72
- Korea University65
- Gene3→61
- Genome5→47
- Identification (biology)3→24
- CRISPR3→16
- Transcription factor1→13
- Gene2→43
- Cancer2→30
- microRNA1→9
- Cancer therapy1→6
- Disease1→26
- Diabetes mellitus1→5
Where bioinformatics is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in South Korea
South Korea bioinformatics patent filing is cooling — 20 filings from 6 assignees (2016–2025), led by Korea Basic Science INST, Pharmcadd, Deargen; annual filings 2→1.
- Korea Basic Science INST10
- Pharmcadd7
- Deargen3
- Samsung3
- Istech2
- Gardner Steve1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.